Affordable Access

Impact of Visceral Metastasis on Efficacy of Fulvestrant in Patients with Hormone Receptor-positive Recurrent Breast Cancer.

Authors
  • Koi, Yumiko1
  • Koga, Chinami2
  • Akiyoshi, Sayuri3
  • Masuda, Takanobu2
  • Ijichi, Hideki2
  • Nakamura, Yoshiaki2
  • Ishida, Mayumi2
  • Ohno, Shinji3
  • Tokunaga, Eriko4
  • 1 Surgical Oncology, Division of Radiation Biology and Medicine, Graduate School of Biochemical & Health Sciences, Hiroshima University, Hiroshima, Japan. , (Japan)
  • 2 Department of Breast Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan. , (Japan)
  • 3 Breast Center, The Cancer Institute Hospital of the Japanese Foundation of Cancer Research, Tokyo, Japan. , (Japan)
  • 4 Department of Breast Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan [email protected] , (Japan)
Type
Published Article
Journal
Anticancer Research
Publisher
International Institute of Anticancer Research
Publication Date
Mar 01, 2018
Volume
38
Issue
3
Pages
1579–1584
Identifiers
PMID: 29491088
Source
Medline
Keywords
License
Unknown

Abstract

Fulvestrant is more effective for patients with non-visceral metastasis of recurrent breast cancer with than for those with visceral metastasis.

Report this publication

Statistics

Seen <100 times